Cargando…
2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children
BACKGROUND: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3) are common respiratory illnesses in children. Two investigational vaccines, mRNA-1345, encoding the RSV prefusion stabilized F (preF) glycoprotein, and mRNA-1653, encoding the hMPV and...
Autores principales: | Snape, Matthew D, Ghamloush, Sabine Schnyder, Chen, Grace L, Dhar, Rakesh, Mithani, Runa, Righi, Vinicius, Morsy, Louie, Kapoor, Archana, Girard, Bethany, Asmar, Laila El, Shaw, Christine A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677146/ http://dx.doi.org/10.1093/ofid/ofad500.2266 |
Ejemplares similares
-
234. Safety and Immunogenicity of mRNA-1345, an mRNA-Based RSV Vaccine in Younger and Older Adult Cohorts: Results from a Phase 1, Randomized Clinical Trial
por: Chen, Grace L, et al.
Publicado: (2022) -
mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022) -
mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023) -
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults
por: August, Allison, et al.
Publicado: (2022) -
Dangers of mRNA vaccines
por: Ali, Tahoora, et al.
Publicado: (2021)